current
treat
patient
particularli
afflict
sever
pneumonia
challeng
specif
drug
vaccin
avail
therefor
msc
therapi
inhibit
overactiv
immun
system
promot
endogen
repair
improv
lung
microenviron
infect
found
studi
strike
addit
studi
larger
cohort
patient
need
valid
therapeut
intervent
howev
new
studi
publish
journal
age
diseas
team
led
dr
zhao
report
intraven
administr
clinicalgrad
human
mesenchym
stem
cell
msc
seven
patient
coronaviru
diseas
result
improv
function
outcom
facilit
recoveri
sever
acut
respiratori
ill
caus
new
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
new
coronaviru
elicit
pandem
respiratori
ailment
sinc
decemb
first
appear
wuhan
china
dissemin
multipl
countri
world
includ
unit
state
even
painstak
global
restraint
confin
effort
preval
continu
climb
increas
number
new
case
signific
mortal
worldwid
coronavirus
commonli
found
peopl
multipl
speci
anim
sometim
anim
coronavirus
infect
peopl
spread
person
person
one
exampl
caus
mild
sever
symptom
includ
fever
cough
short
breath
sever
case
observ
result
death
pathogenesi
suggest
includ
recognit
angiotensin
convert
enzym
receptor
spike
protein
prime
spike
protein
cellular
transmembran
proteas
serin
facilit
host
cell
entri
spread
sever
respiratori
ill
signific
symptom
infect
volum
number
april
receptor
wide
express
lung
alveolar
type
ii
cell
capillari
endotheli
cell
besid
alveolar
cell
express
infect
lung
viru
lead
cytokin
storm
elev
level
multipl
proinflammatori
cytokin
caus
edema
air
exchang
dysfunct
acut
respiratori
distress
secondari
infect
may
result
death
express
also
seen
tissu
heart
liver
kidney
digest
organ
express
pattern
explain
infect
icu
patient
afflict
acut
respiratori
distress
syndrom
also
complic
myocardi
injuri
arrhythmia
acut
kidney
injuri
shock
death
multipl
organ
dysfunct
syndrom
world
health
organ
proclaim
epidem
global
public
health
emerg
current
treat
patient
particularli
afflict
sever
pneumonia
challeng
specif
drug
vaccin
avail
therefor
identifi
safe
effect
treatment
sever
affect
patient
critic
save
live
studi
dr
zhao
collabor
seven
patient
pneumonia
display
improv
function
outcom
recov
intraven
administr
clinicalgrad
human
msc
chosen
patient
posit
one
display
critic
sever
type
exhibit
sever
type
show
common
type
syndrom
addit
three
patient
sever
type
enrol
placebo
control
msc
infus
patient
display
high
fever
short
breath
low
oxygen
satur
pneumonia
patient
receiv
million
msc
per
kilogram
bodi
weight
symptom
get
wors
observ
close
day
notabl
studi
found
virtual
symptom
subsid
day
receiv
msc
infus
appar
advers
effect
chest
ct
imag
demonstr
chest
pneumonia
infiltr
significantli
subsid
also
major
patient
show
neg
result
nucleic
acid
test
week
two
msc
infus
overal
improv
quit
extraordinari
elderli
patient
critic
condit
infect
msc
employ
extens
cell
therapi
includ
plethora
preclin
research
investig
well
signific
number
clinic
trial
safeti
efficaci
shown
mani
clinic
trial
notabl
exampl
includ
immunemedi
inflammatori
diseas
graftversushost
diseas
system
lupu
erythematosu
improv
function
msc
infus
multipl
diseas
condit
mostli
attribut
immunomodulatori
effect
cell
secret
varieti
paracrin
factor
interact
immun
cell
result
eventu
immunomodul
mechan
underli
improv
msc
infus
patient
also
appear
robust
antiinflammatori
activ
msc
process
evid
multipl
benefici
outcom
includ
increas
number
peripher
lymphocyt
declin
creactiv
protein
wane
overactiv
cytokinesecret
immun
cell
cell
cell
nk
cell
day
circul
blood
moreov
group
regulatori
dendrit
cell
dc
popul
increas
msc
treatment
also
comparison
placebo
group
patient
receiv
msc
display
decreas
level
tumor
necrosi
factoralpha
major
proinflammatori
cytokin
concurr
elev
concentr
antiinflammatori
protein
furthermor
x
rnasequenc
uncov
infus
msc
neg
impli
msc
free
infect
besid
multipl
antiinflammatori
trophic
factor
highli
express
msc
also
kyoto
encyclopedia
gene
genom
kegg
analysi
suggest
msc
involv
antivir
pathway
remark
studi
dr
zhao
colleagu
show
intraven
msc
infus
could
reduc
overactiv
immun
system
support
repair
modul
lung
microenviron
infect
even
elderli
patient
intraven
infus
msc
typic
lead
accumul
lung
secret
multipl
paracrin
factor
factor
like
play
signific
role
protect
rejuven
alveolar
epitheli
cell
counteract
fibrosi
improv
lung
function
msc
infus
would
like
particularli
benefici
elderli
individu
infect
without
comorbid
popul
suscept
induc
pneumonia
result
sever
respiratori
distress
death
immunosenesc
summari
studi
show
intraven
infus
msc
safe
effici
approach
treat
patient
pneumonia
includ
elderli
patient
display
sever
pneumonia
addit
studi
larger
cohort
patient
need
valid
therapeut
intervent
howev
